REG - BioPharma Credit PLC - NEW INVESTMENT OF UP TO US$250 MILLION

Biopharma CreditAnnouncement

07/11/2024 12:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241107:nRSG2693La&default-theme=true

RNS Number : 2693L  BioPharma Credit PLC  07 November 2024

7 November 2024

 

BIOPHARMA CREDIT PLC

(THE "COMPANY")

NEW INVESTMENT OF UP TO US$250 MILLION

 

BioPharma Credit PLC (LSE: BPCR), the specialist life sciences debt
investment trust, is pleased to announce that it, through its fully owned
subsidiary, together with BioPharma Credit Investments V (Master)
LP ("BioPharma-V" and jointly with the Company, the "Lenders") has entered
into a definitive senior secured loan agreement with Geron Corporation
("Geron") (the "Loan Agreement"). The Company will invest up to US$100
million and BioPharma-V will invest up to an additional US$150 million in
parallel, with the Company acting as collateral agent.

Based in the US, Geron is a commercial-stage biopharmaceutical company with a
current market capitalization of ~US2.5 billion committed to extending and
enhancing the lives of people living with  blood cancers. Geron's telomerase
inhibitor RYTELO™ (imetelstat) is approved in the United States for the
treatment of certain adult patients with lower-risk myelodysplastic syndromes
(LR-MDS) with transfusion dependent anemia. Geron is also conducting a pivotal
Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed/refractory
myelofibrosis (R/R MF), as well as studies in other myeloid hematologic
malignancies. Rytelo was launched in the United States on June 27, 2024.  Net
product revenue for the quarter ending September 30, 2024 was US$28.2 million.

Under the terms of the transaction, the Company will invest up to US$100
million across three tranches:

·      Tranche A of US$50 million was drawn on 1 November 2024;

·      Tranche B of US$30 million is available to be drawn by 31
December 2025, subject to customary conditions precedent set forth in the Loan
Agreement; and

·      Tranche C of up to US$20 million will be available upon
achievement of certain revenue milestones and customary conditions precedent
set forth in the Loan Agreement until 31 December 2025.

The loan will mature in November 2029 and will bear interest at 3-month SOFR
plus 5.75 per cent. per annum subject to a 3.00 per cent. SOFR floor, along
with an additional consideration of 2.50 per cent. The additional
consideration with respect to Tranche A was paid at the funding of Tranche A
and will be due and payable with respect to Tranche B and Tranche C at the
funding of those tranches.

Pedro Gonzalez de Cosio, CEO of Pharmakon Advisors, LP, the Company's
investment adviser said:

"The Geron team is driving commercial success in the U.S. with RYTELO, an
innovative first-in-class telomerase inhibitor, and we look forward to
supporting the company and management team as they plan for a potential launch
in the EU and continue to develop the asset in additional hematologic
malignancies."

Enquiries

Burson Buchanan

Mark Court / Jamie Hooper / Henry Wilson / Samuel Adams

+44 (0) 20 7466 5000

biopharmacredit@buchanan.uk.com (mailto:biopharmacredit@buchanan.uk.com)

Notes to Editors

BioPharma Credit PLC is London's only specialist debt investor to the life
sciences industry and joined the LSE in March 2017. The Company seeks to
provide long-term shareholder returns, principally in the form of sustainable
income distributions from exposure to the life sciences industry. The Company
seeks to achieve this objective primarily through investments in debt assets
secured by royalties or other cash flows derived from the sales of approved
life sciences products.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRUPGCGGUPCPGQ